Related Experiment Videos
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations
J B Oldemeyer1, R J Lund, M Koch
1Department of Internal Medicine, Creighton University, Omaha, NE, USA.
Cardiology
|February 15, 2001
Summary
Different statin-fibrate combinations may pose varying risks for rhabdomyolysis. A patient developed rhabdomyolysis and acute kidney injury after switching from pravastatin/fenofibrate to simvastatin/gemfibrozil.
Area of Science:
- Pharmacology
- Nephrology
- Cardiovascular Medicine
Background:
- Statin-fibrate combinations are frequently prescribed for hyperlipidemia management.
- Rhabdomyolysis and acute renal failure are known potential adverse effects of these drug classes.
- The comparative risk of rhabdomyolysis among different statin-fibrate combinations remains unclear.
Observation:
- A case study involving a patient treated for hyperlipidemia is presented.
- The patient was initially on a combination of pravastatin and fenofibrate.
- A switch was made to a combination of simvastatin and gemfibrozil.
Findings:
- The patient experienced rhabdomyolysis with acute renal failure shortly after initiating the simvastatin and gemfibrozil regimen.
- This suggests a potential differential risk profile for rhabdomyolysis between statin-fibrate combinations.
Implications:
- Clinicians should be aware of potential varying risks of rhabdomyolysis with different statin-fibrate combinations.
- Further research is warranted to elucidate the specific risks associated with various statin-fibrate pairings.
- This case highlights the importance of vigilant monitoring for adverse events when altering lipid-lowering drug combinations.